Co-Targeting SOS1 Enhances the Antitumor Effects of KRASG12C Inhibitors by Addressing Intrinsic and Acquired Resistance

Authors

Venu Thatikonda
Hengyu Lyu
Sabine Jurado
Kaja Kostyrko
Christopher A Bristow
Christoph Albrecht
Donat Alpar
Heribert Arnhof
Oliver Bergner
Karin Bosch
Ningping Feng
Sisi Gao
Daniel Gerlach
Michael Gmachl
Melanie Hinkel
Simone Lieb
Astrid Jeschko
Annette A Machado
Thomas Madensky
Ethan D Marszalek
Mikhila Mahendra
Gabriella Melo-Zainzinger
Jessica M Molkentine
Philipp A Jaeger
David H Peng
Robyn L Schenk
Alexey Sorokin
Sandra Strauss
Francesca Trapani
Scott Kopetz
Christopher P Vellano
Mark Petronczki
Norbert Kraut
Timothy P Heffernan
Joseph R Marszalek
Mark Pearson
Irene C Waizenegger
Marco H Hofmann

Publication Date

9-1-2024

Journal

Nature Cancer

DOI

10.1038/s43018-024-00800-6

PMID

39103541

PMCID

PMC11424490

PubMedCentral® Posted Date

8-5-2024

PubMedCentral® Full Text Version

Post-print

Abstract

Combination approaches are needed to strengthen and extend the clinical response to KRAS

Keywords

SOS1 Protein, Proto-Oncogene Proteins p21(ras), Humans, Drug Resistance, Neoplasm, Animals, Mice, Cell Line, Tumor, Colorectal Neoplasms, Xenograft Model Antitumor Assays, Protein Tyrosine Phosphatase, Non-Receptor Type 11, Lung Neoplasms, Mutation, Female, Antineoplastic Combined Chemotherapy Protocols, Acetonitriles, Piperazines, Pyrimidines

Published Open-Access

yes

Recommended Citation

Thatikonda, Venu; Lyu, Hengyu; Jurado, Sabine; et al., "Co-Targeting SOS1 Enhances the Antitumor Effects of KRASG12C Inhibitors by Addressing Intrinsic and Acquired Resistance" (2024). Faculty, Staff and Student Publications. 4635.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/4635